Pfizer Inc. Skyrockets After Covid-19 Vaccine Success | Technical Analysis

The Pfizer Inc. (NYSE: PFE) stock opened with a large positive gap yesterday, following headlines that the company’s coronavirus vaccine candidate, developed in cooperation with Germany-based BioNTech SE, was found to be more than 90% effective in preventing the virus. That said, after hitting resistance at 41.40, the stock pulled back and, at the time of writing, it is trading slightly below the key barrier of 39.15. However, overall, the stock continues to trade above the upside support line drawn from the low of March 23rd and thus, we would consider the broader picture to be positive.

We believe that even if the retreat continues for a while more, the bulls may regain control from near the 38.20 barrier, marked by the high of November 4th, or from near the aforementioned upside support line. They may push the price back up for another test near the 41.40 zone, which if broken, may allow extensions towards the 43.20 area, which prevented the stock from moving higher between July 17th and 26th, 2019.

Looking at our daily oscillators, we see that the RSI runs above 50 and points up, while the MACD lies slightly above both its zero and trigger lines, also pointing north. Both indicators detect strong upside speed and support the notion for another positive leg in this stock.

In order to abandon the bullish case and start examining the case of a deeper decline, we would like to see the price dropping below the low of October 29th, at 34.60. Such a move would not only take the share below the pre-mentioned upside line, but it would also confirm a forthcoming lower low on the daily chart. We may then see declines towards the 33.10 obstacle, marked by the low of July 9th, the break of which could extend the slide towards the low of June 26th, at 31.60.

Disclaimer:

The content we produce does not constitute investment advice or investment recommendation (should not be considered as such) and does not in any way constitute an invitation to acquire any financial instrument or product. The Group of Companies of JFD, its affiliates, agents, directors, officers or employees are not liable for any damages that may be caused by individual comments or statements by JFD analysts and assumes no liability with respect to the completeness and correctness of the content presented. The investor is solely responsible for the risk of his investment decisions. Accordingly, you should seek, if you consider appropriate, relevant independent professional advice on the investment considered. The analyses and comments presented do not include any consideration of your personal investment objectives, financial circumstances or needs. The content has not been prepared in accordance with the legal requirements for financial analyses and must therefore be viewed by the reader as marketing information. JFD prohibits the duplication or publication without explicit approval.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 72.57% of retail investor accounts lose money when trading CFDs with the Company. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please read the full Risk Disclosure.

Copyright 2020 JFD Group Ltd.

Such a large push but if they can get it over the line the EU commission will buy 300million doses so major money for them